ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Jazz Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN21,142 Mil.
Jazz Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2026 was MXN211,898 Mil. Therefore, Jazz Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was 9.98%.
The historical rank and industry rank for Jazz Pharmaceuticals's ROA % or its related term are showing as below:
MEX:JAZZN'
s ROA % Range Over the Past 10 Years
Min: -3.5 Med: 4.37 Max: 9.83
Current: 0.26
During the past 13 years, Jazz Pharmaceuticals's highest ROA % was 9.83%. The lowest was -3.50%. And the median was 4.37%.
MEX:JAZZN's ROA % is ranked better than 80.96% of 1423
companies
in the Biotechnology industry
Industry Median: -33.07
vs MEX:JAZZN: 0.26
Jazz Pharmaceuticals (MEX:JAZZN) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jazz Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's ROA % distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Jazz Pharmaceuticals (MEX:JAZZN) has a ROA % of 9.98% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Jazz Pharmaceuticals and its competitors. This is 128% above median its historical median of 4.37. According to the industry distribution chart, Jazz Pharmaceuticals ranks #271 out of 1423 companies in the Biotechnology industry, placing it in the top 19%.
Is Jazz Pharmaceuticals' ROA % too high?
Jazz Pharmaceuticals' current ROA % of 9.98% is 128% above median its 10-year median of 4.37. Based on the distribution chart, Jazz Pharmaceuticals ranks #271 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' ROA % compare to ASND and SMMT?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #271 out of 1423 companies for ROA %. This places Jazz Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current ROA % is 9.98%, which is 128% above median its own 10-year median of 4.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Jazz Pharmaceuticals (MEX:JAZZN) has a current ROA % of 9.98%. The stock's GF Value™ is MXN1,641.59, compared to a current price of MXN2,500.00 — trading 52.3% above its estimated fair value. The current ROA % is 9.98%, which is 128% above median its 10-year median of 4.37. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Jazz Pharmaceuticals (MEX:JAZZN), the current ROA % is 9.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (MEX:JAZZN) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN2,500.00 is trading 52.3% above its estimated GF Value™ of MXN1,641.59.
Key valuation signals for MEX:JAZZN:
ROA %: 9.98% (128% above median its 10-year median of 4.37)
GF Value™: MXN1,641.59 vs. price of MXN2,500.00 (52.3% above fair value)
No single metric tells the full story. See the MEX:JAZZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for MEX:JAZZN
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:JAZZN has been successfully added to your 
